公司代码：600129 公司简称：太极集团 重庆太极实业（集团）股份有限公司 2024 年度内部控制评价报告 重庆太极实业（集团）股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由 ...

目 录 | 一、审计报告……………………………………………………… 第 1—6 | | | 页 | | --- | --- | --- | --- | | 二、财务报表……………………………………………………… 第 7—15 | | | 页 | | （一）合并资产负债表…………………………………………… | 第 | 7 | 页 | | （二）母公司资产负债表………………………………………… | 第 | 8 | 页 | | （三）合并利润表………………………………………………… | 第 | 9 | 页 | | （四）母公司利润表………………………………………………第 | | 10 | 页 | | （五）合并现金流量表……………………………………………第 | | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | | 12 | 页 | | （七）合并所有者权益变动表……………………………… 第 13-14 | | | 页 | | （八）母公司所有者权益变动表…………………………………第 | | 15 | 页 | 三、财务报表附注……………………………………………… 第 16—123 ...

1 | 明细 | 金额（万元） | | --- | --- | | 募集资金净额【注 1】 | 196,239.98 | | 加：利息收入（扣除银行手续费）净额 | 4,765.97 | | 减：置换先期已投入募集资金投资项目的自筹资金 | 14,826.07 | | 减：2018 年年初至今实际投入募投项目使用的募集资金 | 162,443.17 | | 减：闲置募集资金暂时补充流动资金 | 17,000 | | 减:终止募投项目永久补充流动资金(含利息收入) | 4,109.97 | | 2024 年 12 月 31 日募集资金专户余额 | 3,066.63 | | 差异【注 2】 | 439.89 | 【注 1】募集资金专户初始余额为主承销商东方证券股份有限公司扣除承销和保荐费 用后汇入金额，扣除股权登记费、会计师费、律师费等与发行权益性证券直接相关的其他发 行费用。 【注 2】本期应结余募集资金与实际结余募集资金差异系扣除的股权登记费、会计师 费、律师费等与发行权益性证券直接相关的其他发行费用 439.89 万元。 证券代码：600129 证券简称：太极集团 公告编号：2025-025 重庆太极实业（ ...

为真实、客观、公允地反映公司 2024 年度的财务状况和经营成果， 按照《企业会计准则》等相关规定，基于谨慎性原则，公司于年末对 可能出现减值迹象的相关资产进行了检查和减值测试，2024 年度计提 资产减值准备和信用减值准备 5,121.01 万元。具体详见下表： 证券代码：600129 证券简称：太极集团 公告编号：2025-022 重庆太极实业（集团）股份有限公司 2024 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称"公司"）第十 届董事会第二十七次会议、第十届监事会第二十二次会议审议通过了 《关于 2024 年度计提资产减值准备的议案》。现将具体情况公告如下： 一、本次计提减值准备的情况概述 | 项目 | 计提减值准备金额（万元） | | --- | --- | | 资产减值损失 | 4,318.94 | | 信用减值损失 | 802.07 | | 合计 | 5,121.01 | 一、本次计提资产减值准备的相关说明 （一）计提资产减值准备的方法 ...

Financial Performance - The company's net profit attributable to shareholders for 2024 is CNY 26,652,727.94, a decrease of 96.76% compared to CNY 822,124,918.06 in 2023[8]. - Total revenue for 2024 is CNY 12,386,016,983.42, reflecting a decline of 20.72% from CNY 15,622,648,416.93 in 2023[26]. - The net cash flow from operating activities for 2024 is CNY -631,462,933.69, a significant drop from CNY 671,536,615.17 in 2023, representing a change of -194.03%[26]. - The company's total assets decreased by 2.46% to CNY 14,057,759,232.64 at the end of 2024, down from CNY 14,411,774,083.52 at the end of 2023[26]. - The net assets attributable to shareholders decreased by 3.59% to CNY 3,492,167,957.47 at the end of 2024, compared to CNY 3,622,185,106.00 at the end of 2023[26]. - The company reported a net profit excluding non-recurring gains and losses of CNY 38,539,284.46 for 2024, down 95.02% from CNY 774,448,432.63 in 2023[26]. - The company will not distribute profits for 2024, citing significant future operational funding needs[8]. Sales and Revenue Breakdown - The company achieved a revenue of 12.386 billion RMB in 2024, a decrease of 20.72% year-on-year[37]. - The pharmaceutical manufacturing segment reported sales of 7.038 billion RMB, a decline of 32.25% year-on-year[37]. - The pharmaceutical commerce segment generated sales of 6.740 billion RMB, down 9.00% year-on-year[37]. - The traditional Chinese medicine resources segment saw sales of 1.053 billion RMB, an increase of 0.82% year-on-year[37]. - The health and international business segment achieved sales of 461 million RMB, a growth of 39.43% year-on-year[37]. Research and Development - The company has 61 ongoing research projects, including 19 in traditional Chinese medicine and 18 in chemical medicine[38]. - The company obtained 10 drug registration standards and 48 patent authorizations during the reporting period[38]. - The company recruited 2 PhDs and 31 Masters to enhance its research talent pool[39]. - The company established two major innovation centers in Fuling and Chongqing to improve its research capabilities[39]. - The company successfully integrated 13 products into 10 treatment guidelines, 19 expert consensus documents, and 11 treatment/prevention plans during the reporting period[40]. - The company’s R&D expenses increased by 19.67% to 279.57 million RMB, reflecting a commitment to innovation[70]. - The company is focusing on R&D and innovation to adapt to the evolving regulatory landscape in the pharmaceutical industry[90]. Market and Product Development - The company is strategically expanding its import and export business, with significant new market entries in regions such as Singapore, Indonesia, and the UAE[47]. - The company is actively restructuring its marketing organization to enhance management efficiency and has streamlined its functional departments to 16[49]. - The company’s marketing strategy includes cross-industry promotions and collaborations to enhance brand visibility among younger consumers[42]. - The company aims to enhance its core competitiveness through innovative drug development, focusing on 12 major diseases and leveraging modern technology[58]. - The company is exploring potential mergers and acquisitions to strengthen its product portfolio and market share in the healthcare industry[93]. Operational Efficiency and Cost Management - The company’s production capacity construction includes the establishment of a "Lighthouse Factory" at the Fuling Pharmaceutical Plant, enhancing manufacturing capabilities[43]. - The company’s comprehensive energy consumption per 10,000 yuan of output value was 0.0582 tons of standard coal, which is 2.7% lower than the target value[43]. - The company has a centralized procurement model that enhances efficiency and reduces costs, implementing strict quality control measures and supplier management to optimize the supply chain[56]. - The company plans to enhance product quality and reduce production costs in response to the competitive pricing pressures from national drug procurement policies[91]. - The company is focusing on establishing stable relationships with quality suppliers to control raw material costs effectively[137]. Governance and Shareholder Relations - The company has established a three-year shareholder return plan for 2024-2026 to enhance investor trust and protect their rights[144]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[144]. - The company emphasizes investor relations management, maintaining close communication with investors through various channels[143]. - The board of directors held eight meetings, with independent directors providing valuable insights for the company's long-term development[142]. - The company has organized two shareholder meetings in the reporting period, ensuring equal voting rights and transparency in decision-making[141]. Environmental and Social Responsibility - Environmental protection investments during the reporting period totaled CNY 10.86 million[192]. - The company operates wastewater treatment facilities with a daily capacity of 450 tons and 300 tons for its subsidiaries, ensuring compliance with relevant discharge standards[196][197]. - Emergency response plans for environmental incidents have been developed and filed by both Southwest Pharmaceutical and Zhejiang Oriental[199]. - The company has established an internal control system focusing on compliance management and risk prevention, enhancing operational management levels[188]. Future Outlook - The company provided a positive outlook for 2024, projecting a revenue growth of 10-12%[151]. - The company aims to achieve a revenue growth target of 10% for the upcoming fiscal year[149]. - The company plans to invest in new technologies to improve operational efficiency and product quality[149]. - The company is committed to maintaining transparency and accountability in its financial reporting practices[149].

二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 24839.28万股，累计占流通股比： 44.61%，较上期变化： -891.08万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 太极集团（600129）有限公司 | 15381.24 | 27.62 | 不变 | | 重庆市涪陵页岩气产业投资发展有限公司 | 4409.53 | 7.92 | 不变 | | 重庆市涪陵区希兰生物科技有限公司 | 1189.53 | 2.14 | 不变 | | 富国研究精选灵活配置混合A | 588.54 | 1.06 | 新进 | | 重庆市涪陵实业发展集团有限公司 | 585.68 | 1.05 | 不变 | | 香港中央结算有限公司 | 561.36 | 1.01 | -531.47 | | 南方中证500ETF | 556.67 | 1.00 | -82.13 | | 富国天惠成长混合(LOF) | 540.77 | 0.97 | 新进 | | 中国人寿（601628）保险股份有限公司-传 ...

Core Viewpoint - Taiji Group's subsidiaries are required to pay approximately 100 million yuan in back taxes and penalties, significantly impacting the company's projected net profit for 2024, which is expected to drop to 26.65 million yuan, a decrease of about 96.76% compared to 2023 [1][2] Group 1: Tax Payment and Financial Impact - The tax payment involves two subsidiaries: Southwest Pharmaceutical Co., Ltd. and Chongqing Chinese Medicinal Materials Co., Ltd., with Southwest Pharmaceutical responsible for approximately 80 million yuan and Chongqing Chinese Medicinal Materials for about 20 million yuan [2] - The expected net profit for 2024 was revised down from 156.4 million yuan to 26.65 million yuan due to the tax payment, indicating a substantial decline in profitability [2][4] - If non-recurring gains and losses are excluded, the net profit is projected to be around 38.54 million yuan, reflecting a year-on-year decline of 95.02% [2] Group 2: Regulatory and Compliance Issues - The tax issue follows a recent penalty related to quality control problems in the production of a specific anesthetic drug, which raises concerns about the company's compliance and operational integrity [1][5] - The regulatory scrutiny may lead to a downgrade in credit ratings for Southwest Pharmaceutical, potentially affecting its eligibility for national drug procurement in the next three years [3][5] - The company emphasizes that the tax payment does not involve administrative penalties and plans to enhance supervision and training regarding tax compliance [4][9] Group 3: Strategic Goals and Market Position - Taiji Group aims to achieve a revenue target of 50 billion yuan by 2025, but recent events have raised doubts about its ability to meet this goal, given the significant drop in projected profits and ongoing compliance issues [8][9] - The company has experienced a steady increase in revenue from 112.08 billion yuan in 2020 to 156.23 billion yuan in 2023, but the gap to the 50 billion yuan target remains considerable [8] - Balancing rapid expansion with compliance in a tightening regulatory environment poses a significant challenge for the company's management [9]

Core Viewpoint - Taiji Group announced a significant downward adjustment in its 2024 profit forecast, with a projected net profit decline of 96.76% due to tax payments and decreased sales in key product categories [1][2]. Group 1: Financial Performance - The company initially forecasted a net profit of approximately 156 million yuan for 2024, representing a year-on-year decline of about 80.98% [1]. - The revised forecast estimates a net profit of around 26.65 million yuan, marking the lowest level in nearly a decade, excluding losses in 2014, 2019, and 2021 [1]. - Revenue for 2024 is expected to decrease by approximately 32.13 billion yuan, with a decline rate of 20.56%, particularly impacted by a 42.5% drop in fourth-quarter revenue [1]. Group 2: Tax Payments - Two subsidiaries of Taiji Group, Southwest Pharmaceutical Co., Ltd. and Chongqing Chinese Medicinal Materials Co., Ltd., are required to pay a total of about 100 million yuan in taxes and penalties [2]. - Southwest Pharmaceutical is responsible for 80 million yuan in income tax, while Chongqing Chinese Medicinal Materials must pay 20 million yuan in value-added tax and penalties [2]. - The tax payments will be recorded in the 2024 fiscal year and do not involve any administrative penalties [2]. Group 3: Market Performance - On March 27, Taiji Group's stock closed at 20.88 yuan per share, reflecting a decline of 1.09% [3].

济民健康一副总裁涉嫌犯罪；太极集团两子公司补 缴税款及滞纳金1亿元｜医药早参 每经记者 陈星 每经编辑 董兴生 ｜ 2025年3月27日 星期四 ｜ NO.1 济民健康副总裁何清红涉嫌犯罪 济民健康公告，公司副总裁何清红及其团队成员于2023年3月私刻了公司及其子公司（聚民生物科技有 限公司、浙江济民堂医药贸易有限公司）的印章，并在销售过程中，冒用公司名义用假章与经销商签署 《补充协议》，约定若经销商在一定期限内（如3个月、6个月）没有实现产品销售，在不影响二次销售 的情况下，有权退回公司，公司需给予经销商所退回产品采购金额10%的资金占用补偿。 点评：何清红于2022年2月加入济民健康，任副总裁职务，主要负责预充式导管冲洗器及安全注射器国 内市场的营销工作。2023年和2024年，何清红团队合计实现销售额约11719.90万元。济民健康可能因该 事件存在被经销商起诉、退货退款并支付资金占用补偿的风险。 NO.2 太极集团下调2024年业绩预告 因控股子公司和全资子公司根据当地税务检查和企业自查情况，两子公司需补缴税款和滞纳金共计约1 亿元。上述补缴税款和滞纳金计入太极集团2024年当期损益，公司因此下调20 ...